Overview
HIV/AIDS in Niger refers to the prevalence, incidence, and impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) within the Republic of Niger, a land‑locked country in West Africa. The disease is a public health concern, though the national prevalence has historically been among the lowest in the region.
Epidemiology
- Prevalence: According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Niger Ministry of Public Health, the adult (15‑49 years) HIV prevalence has remained below 1 % throughout the 2000s and 2010s. The most recent estimates (2022) place the prevalence at approximately 0.5 % among adults, representing roughly 50 000–70 000 people living with HIV (PLHIV) in a population of about 25 million.
- Incidence: Annual new infections have been estimated at 1 000–2 000 cases per year in recent reporting cycles, reflecting a relatively stable but low transmission rate.
- Geographic distribution: Higher prevalence rates have been observed in urban centers such as Niamey (the capital) and Zinder, as well as in regions bordering Nigeria and Burkina Faso, where cross‑border mobility contributes to exposure risk.
- Key populations: Sex workers, men who have sex with men (MSM), people who inject drugs (PWID), and migrant workers are identified by the national AIDS program as groups with elevated risk, though reliable disaggregated data are limited.
Historical Trends
- 1990s: The first documented HIV cases in Niger emerged in the early 1990s, primarily among travelers and sex workers. Surveillance capacity was limited, and prevalence estimates were uncertain.
- 2000–2010: With the establishment of the National AIDS Control Programme (PNLS) in 2004 and support from the Global Fund, prevalence estimates began to be systematically collected through sentinel surveillance in antenatal clinics and population‑based surveys. The prevalence remained below 1 % throughout this period.
- 2010–2020: Scaling up of voluntary counselling and testing (VCT), prevention of mother‑to‑child transmission (PMTCT) services, and antiretroviral therapy (ART) provision contributed to a modest decline in new infections and AIDS‑related mortality. The 2019 Demographic and Health Survey (DHS) reported an adult prevalence of 0.5 %, consistent with UNAIDS estimates.
Government Response and Policies
- National AIDS Control Programme (PNLS): Coordinates prevention, treatment, and care activities; develops the national strategic plan for HIV/AIDS (most recent 2021‑2025).
- Testing and Counselling: Community‑based and facility‑based VCT services are offered free of charge. Rapid diagnostic tests are used in health centers and through mobile outreach.
- Treatment: ART is provided at no cost through the public health system. As of 2022, approximately 70 % of diagnosed PLHIV were estimated to be on ART, aligning with the UNAIDS 95‑95‑95 targets. First‑line regimens follow WHO recommendations (e.g., tenofovir + lamivudine + dolutegravir).
- Prevention of Mother‑to‑Child Transmission (PMTCT): Integration of HIV testing into antenatal care has enabled early identification of pregnant women living with HIV; the majority receive lifelong ART, reducing vertical transmission rates to under 5 % in recent cohorts.
- Education and Outreach: The Ministry, in partnership with NGOs and community‑based organizations, conducts awareness campaigns focusing on condom use, safe sex, and reduction of stigma.
International Assistance
- Global Fund: Provides multi‑year financing for HIV prevention, treatment, and health system strengthening.
- PEPFAR (U.S. President’s Emergency Plan for AIDS Relief): Supports ART procurement, laboratory capacity, and capacity‑building for healthcare workers.
- UN agencies (UNAIDS, WHO, UNICEF): Offer technical assistance, policy guidance, and support for data collection and monitoring.
Challenges
- Data limitations: Sparse disaggregated data for key populations hinder precise targeting of interventions.
- Stigma and discrimination: Social stigma remains a barrier to testing and treatment uptake, particularly among women and marginalized groups.
- Geographic access: Rural and remote areas have limited health infrastructure, affecting service delivery.
- Funding sustainability: Dependence on external donors raises concerns about long‑term financing of ART and prevention programs.
Outlook
Given the low baseline prevalence and continued expansion of testing and treatment services, Niger is positioned to maintain relatively low HIV transmission rates. Ongoing efforts focus on closing gaps in coverage for key populations, strengthening surveillance, and ensuring the sustainability of ART provision to achieve the UNAIDS 95‑95‑95 targets.
